House
Sign inCreate account
Drug lookup
Drug reference

talazoparib

PARP inhibitor · null

PARP inhibitornullATC null
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
X
FDA category + note
Top interactionssee all 12 →
  • AdalimumabSevereDatabaseDDInter
  • AmiodaroneSevereDatabaseDDInter
  • BaricitinibSevereDatabaseDDInter
  • CarvedilolSevereDatabaseDDInter

Mechanism

Talazoparib inhibits poly(ADP-ribose) polymerase (PARP) in cancers with BRCA mutations.

Indications

breast cancer (BRCA mutation)ovarian cancer (BRCA mutation)pancreatic cancer (BRCA mutation)prostate cancer (BRCA mutation)BRCA-mutated, HER2-negative, locally advanced or metastatic breast cancer

Pharmacokinetics

Half-life
90 h (elimination)
Metabolism
minimal hepatic metabolism
Excretion
mostly in the urine

Side effects

Common
anemia (highest occurrence rate among PARP inhibitors)neutropeniathrombocytopenia
Serious
  • MDS
  • AML (0.3% of patients)
  • myelosuppression

Pregnancy & lactation

Pregnancy

X

Drug interactions

Adalimumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Amiodarone
Severe
Database

Drug interaction classified as: absorption

Source: DDInter

Baricitinib
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Carvedilol
Severe
Database

Drug interaction classified as: absorption

Source: DDInter

Certolizumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Cladribine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Clarithromycin
Severe
Database

Drug interaction classified as: absorption

Source: DDInter

Clozapine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Deferiprone
Severe
Database

Clinical effect not specified

Source: DDInter

Etanercept
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Fingolimod
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Golimumab
Severe
Database

Clinical effect not specified

Source: DDInter

Related guidelines

Breast cancer
ESMO · Oncology · 2024
Breast cancer
ICMR · Oncology · 2022
Cervical cancer screening and management
ICMR · Oncology · 2022
Tobacco-related cancer prevention
ICMR · Oncology · 2021
Lung cancer
ESMO · Oncology · 2024

Other PARP inhibitor drugs

olaparib
0 brands

Ask House about talazoparib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team